Which drug is included in the multiple drug therapy regimen for multibacillary leprosy but not in the standard adult regimen for paucibaccipary leprosy
Clofazimine is the drug included in the multibacillary (MB) leprosy regimen but not in the paucibacillary (PB) regimen.
- Paucibacillary leprosy (standard adult): Dapsone 100 mg daily + Rifampicin 600 mg monthly (supervised) - for 6 months.
- Multibacillary leprosy (standard adult): Dapsone 100 mg daily + Clofazimine 50 mg daily + Rifampicin 600 mg monthly + Clofazimine 300 mg monthly (supervised) - for 12 months.
So clofazimine is the additional drug in the MB regimen. It provides bactericidal activity and has anti-inflammatory properties that help control erythema nodosum leprosum (ENL) reactions.
What are the side effects of clofazimine?
Clofazimine has a well-known side effect profile, with skin discoloration being the most prominent. Let me pull up the full details from the medical library.
Searching sources...
Reading File
Finding Sources
Searching PubMed
clofazimine adverse effects
Reading File
Reading File
Reading File
Here is a detailed breakdown of clofazimine's side effects, drawn from multiple authoritative textbooks:
Side Effects of Clofazimine
1. Skin and Mucocutaneous (Most Prominent)
- Skin discoloration - the most well-known and clinically significant cosmetic effect. The skin turns red to red-brown diffusely, with bluish to violet-brown pigmentation at lesional sites. This is due to drug deposits within fat and macrophages.
- Discoloration also affects the conjunctivae and cornea.
- Body fluids (urine, sweat, tears) can become discolored.
- Xerosis/ichthyosis (dry, scaly skin).
- The discoloration resolves gradually after stopping the drug, but it is a major reason patients refuse or discontinue treatment.
2. Gastrointestinal (Common)
- Abdominal pain, nausea, vomiting, diarrhea.
- At high doses (e.g., 300 mg/day used for recurrent ENL), GI effects can be significant and dose-limiting.
- Rare but serious: crystal deposition-related enteropathy (from drug crystals accumulating in intestinal macrophages).
3. Ocular
- Ocular irritation (conjunctival and corneal discoloration mentioned above also falls here).
4. Hepatic
- Elevated liver enzymes (hepatotoxicity) - especially with daily doses above 100 mg. Periodic LFTs are recommended in such cases.
5. Cardiac (Rare)
- Cardiac arrhythmias - rare, typically associated with electrolyte disturbances. A baseline electrolyte panel is recommended before starting therapy.
Key Monitoring Guidelines
| Parameter | When |
|---|---|
| Electrolyte panel | Baseline |
| Liver function tests | Periodically if dose >100 mg/day |
| GI symptoms & skin discoloration | Periodic clinical evaluation |
Special Considerations
- Pregnancy/Lactation: Should be avoided - clofazimine concentrates in breast milk.
- Pharmacokinetics: Due to its extremely long serum half-life (~2 months) and storage in reticuloendothelial tissues and skin, side effects - especially discoloration - can persist long after the drug is stopped.
- Contraindication: Prior hypersensitivity reaction.
Sources: Katzung's Basic and Clinical Pharmacology 16e; Dermatology 2-Volume Set 5e; Harrison's Principles of Internal Medicine 22e (2025)
Regimen for leprosy
Searching sources...
Finding Sources
Reading File
Reading File
Reading File
Here is the complete WHO MDT (Multidrug Therapy) regimen for leprosy:
WHO MDT Regimen for Leprosy
Classification (WHO, skin lesion-based)
| Type | Skin Lesions | Nerve Involvement |
|---|---|---|
| Paucibacillary (PB) | 1-5 lesions | Only 1 nerve |
| Multibacillary (MB) | 6 or more lesions | More than 1 nerve |
A. Multibacillary (MB) Leprosy
Adults
| Drug | Dose | Administration |
|---|---|---|
| Rifampicin | 600 mg | Once monthly, supervised |
| Dapsone | 100 mg | Daily, self-administered |
| Clofazimine | 300 mg | Once monthly, supervised |
| Clofazimine | 50 mg | Daily, self-administered |
Duration: 12 monthly doses (MB blister packs), to be completed within 18 months
Children (10-14 years)
| Drug | Dose | Administration |
|---|---|---|
| Rifampicin | 450 mg | Once monthly, supervised |
| Dapsone | 50 mg | Daily, self-administered |
| Clofazimine | 150 mg | Once monthly, supervised |
| Clofazimine | 50 mg | Every other day, self-administered |
B. Paucibacillary (PB) Leprosy
Adults
| Drug | Dose | Administration |
|---|---|---|
| Rifampicin | 600 mg | Once monthly, supervised |
| Dapsone | 100 mg | Daily, self-administered |
Duration: 6 monthly doses (PB blister packs), to be completed within 9 months
Children (10-14 years)
| Drug | Dose | Administration |
|---|---|---|
| Rifampicin | 450 mg | Once monthly, supervised |
| Dapsone | 50 mg | Daily, self-administered |
Children under 10 years receive appropriately reduced doses.
C. Special Situations
Clofazimine Refusal (skin discoloration unacceptable)
- Clofazimine may be replaced by ethionamide or protionamide 250-375 mg daily (self-administered) in the MB regimen.
HIV Co-infection
- MDT is not contraindicated; management and response are the same as HIV-negative patients.
Pregnancy
- MDT should be continued - evidence shows it is safe. Mild skin discoloration in the infant from clofazimine in breast milk may occur but is not harmful.
D. Adequate Treatment Criteria
- PB: 6 monthly doses within 9 months
- MB: 12 monthly doses within 18 months
Source: Park's Textbook of Preventive and Social Medicine; Harrison's Principles of Internal Medicine 22e (2025)
This is a shared conversation. Sign in to Orris to start your own chat.